Simvastatin and Pediatric Craniofacial Bone Healing: A Critical Narrative Review

Craniofacial bone healing in children presents distinct biological and clinical chal-lenges. Unlike adults, pediatric craniofacial bone exhibits active growth plates, higher turno-ver, and greater remodeling capacity, which complicates reconstruction following congenital anomalies, trauma, or surgical interventions. Simvastatin, a cholesterol-lowering drug with pleiotropic effects, has gained attention in regenerative medicine due to its osteopromotive and anti-inflammatory properties. This narrative review synthesizes preclinical data, clinical trials, and pediatric-specific considerations regarding simvastatin in craniofacial bone healing. Mech-anistically, simvastatin enhances bone morphogenetic protein-2 (BMP-2) expression, promotes angiogenesis through vascular endothelial growth factor (VEGF), suppresses osteoclast-medi-ated resorption by modulating the RANKL/OPG pathway, and reduces inflammatory cytokines via NF-κB inhibition. Together, these effects provide a supportive environment for bone re-generation. Animal studies in rats, rabbits, and dogs consistently demonstrate increased bone volume, mineral density, and osteogenic marker expression following simvastatin administra-tion. Limited human clinical studies, mostly in adults, have reported improved socket healing and enhanced radiographic bone density after localized application. However, evidence in pe-diatric populations remains scarce. As pediatric bone differs in growth dynamics and systemic metabolism, age-specific trials are needed. Ethical concerns, uncertain dosing regimens, and potential systemic effects on cholesterol metabolism, puberty, and skeletal development high-light the importance of cautious translation into clinical practice. Simvastatin may offer a min-imally invasive pharmacologic strategy that complements surgical interventions in pediatric craniofacial reconstruction. Although promising evidence exists, rigorous pediatric trials, op-timized delivery systems, and long-term growth monitoring are essential before its clinical ap-plication can be broadly recommended.